Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it ...

In an era where most carmakers are clutching their pearls over rising costs, falling margins, and the existential dread of ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

It’s an Aston-Martin silencer. A Lucid humbler ... of course, they own the patent. Private Office commissions command a 25% premium over even standard Bespoke orders. But they come with a ...

A federal jury in San Francisco has handed down a unanimous verdict clearing Motive Technologies Inc. of allegations it copied patents owned by technology developer Omnitracs. The jury’s April ...

In this patent, Dr Amol Vibhute, Dr Rajesh Dhumal, and Dr Rupali Surase also contributed significantly to the research work. “The newly patented methodology uniquely integrates satellite remote ...

A century ago, when the Japanese sought the “secret sauce” behind America’s rapid rise, they found a compelling answer: the U.S. patent system. A strong patent system would serve as a far ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

Expected to hit dealer lots for the 2026 model year, the redesigned crossover has been indirectly leaked by patent images from EUIPO. First uncovered by Quattroruote Italia, the design patent ...

Lewistown native Luke Ployhar, founder of Blue Arc LLC, purchased almost 60 patents in the Zortman Mine Complex in 2001. A 1995 Montana State University graduate, he owns Afterglow Studios ...

Modified silencers roar louder than trucks, honking is constant even when unneeded, and loudspeakers blare without being mindful about the residents. This isn’t just annoying—it’s a serious ...